Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Artrya Limited ( (AU:AYA) ).
Artrya Limited has completed Tranche 1 of its share placement, raising approximately A$60 million, with shares priced at $2.05 each. This placement, aimed at professional and sophisticated investors, is part of a larger A$75 million two-tranche initiative, with Tranche 2 pending shareholder approval. Additionally, a Share Purchase Plan (SPP) will allow eligible shareholders to purchase additional shares at the same price, with the SPP opening on 15 September 2025 and closing on 3 October 2025. This capital raising effort is expected to bolster Artrya’s operations and enhance its market positioning in the medical technology industry.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnoses. Artrya is committed to advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 561,793
Technical Sentiment Signal: Buy
For an in-depth examination of AYA stock, go to TipRanks’ Overview page.